Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting
services and software for pharmaceutical discovery and development,
today announced that it has expanded its product portfolio with the
release of version 1.0 of its MembranePlus™
simulation software.
Mr. John DiBella, vice president for marketing and sales of Simulations
Plus, said, “Simulations Plus continues to expand its product line with
frequent release enhancements of our existing line of software products,
and now the release of MembranePlus 1.0, our first completely new
software product since DDDPlus™
was released about 10 years ago. This new software program is expected
to appeal to a wide audience of pharmaceutical companies who use in
vitro measurements of molecule permeabilities to estimate the likely
permeability in preclinical species as well as humans.”
James Mullin, product manager for MembranePlus and member of the
simulation technologies team in Simulations Plus, added, “Thanks to our
associates from Absorption Systems, LLC, in Exton, PA, we were provided
with the detailed experimental data from permeability measurements for
more than 40 drugs in Caco-2 cell experiments, which enabled us to
calibrate and validate the simulation model in MembranePlus. We believe
MembranePlus is a unique, science-based simulation that will provide
valuable insight into the results of in vitro permeability
experiments to guide researchers to better project decisions.”
Dr. Viera Lukacova, team leader for simulation technologies in
Simulations Plus, said: “The pharmaceutical industry uses a limited
variety of laboratory experiments using cell cultures and artificial
membranes to try to determine how well new molecules will be absorbed
into cells in the gastrointestinal tract of animals and humans.
Unfortunately, the results of such experiments for the same molecules
can vary widely across different laboratories. These differences are
entirely caused by changes in experimental setups, but have not been
easily understood because of the number of factors involved and the
complexity of the interactions among them. By developing MembranePlus,
we can provide a cellular simulation model to account for how measured
permeabilities are affected by a variety of factors in the experimental
conditions and how to interpret the results of experiments from
different laboratories. In addition, MembranePlus will provide a tool to
interpret in vitro data for substrates of cell membrane
transporters and to derive appropriate inputs for binding affinity
constants to be used in the GastroPlus™
in vivo simulations.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug
discovery and development simulation and modeling software, which is
licensed to and used in the conduct of drug research by major
pharmaceutical, biotechnology, agrochemical, and food industry companies
worldwide. Simulations Plus also recently acquired Cognigen,
Inc. of Buffalo, NY, adding top-quality clinical trial data analysis
to our offerings, as well as more than doubling our staff from 30 to 65,
adding nearly 50% to revenues, and increasing earnings in the coming
fiscal year that began September 1. We also provide a productivity tool
called Abbreviate! for PCs. Simulations Plus, Inc., is headquartered in
Southern California and trades on the NASDAQ Capital Market under the
symbol “SLP.” For more information, visit our Web site at www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation Reform
Act of 1995 – With the exception of historical information, the
matters discussed in this press release are forward-looking statements
that involve a number of risks and uncertainties. Words like “believe,”
“expect” and “anticipate” mean that these are our best estimates as of
this writing, but that there can be no assurances that expected or
anticipated results or events will actually take place, so our actual
future results could differ significantly from those statements. Factors
that could cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages, the
general economics of the pharmaceutical industry, our ability to finance
growth, our ability to continue to attract and retain highly qualified
technical staff, our ability to identify and close acquisitions on terms
favorable to the Company, and a sustainable market. Further information
on our risk factors is contained in our quarterly and annual reports as
filed with the U.S. Securities and Exchange Commission.
Copyright Business Wire 2014